SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.

Autor: Nelde A; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Bilich T; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Heitmann JS; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Maringer Y; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Salih HR; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany., Roerden M; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany., Lübke M; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany., Bauer J; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany., Rieth J; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany., Wacker M; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany., Peter A; Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic Laboratory Medicine, University Hospital Tübingen, Tübingen, Germany., Hörber S; Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic Laboratory Medicine, University Hospital Tübingen, Tübingen, Germany., Traenkle B; NMI, Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany., Kaiser PD; NMI, Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany., Rothbauer U; NMI, Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.; Pharmaceutical Biotechnology, University of Tübingen, Tübingen, Germany., Becker M; NMI, Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany., Junker D; NMI, Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany., Krause G; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.; TWINCORE GmbH, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany.; German Center for Infection Research, Braunschweig, Germany., Strengert M; Department of Epidemiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.; TWINCORE GmbH, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany., Schneiderhan-Marra N; NMI, Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany., Templin MF; NMI, Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany., Joos TO; NMI, Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany., Kowalewski DJ; Immatics Biotechnologies GmbH, Tübingen, Germany., Stos-Zweifel V; Immatics Biotechnologies GmbH, Tübingen, Germany., Fehr M; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany., Rabsteyn A; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; Department of General Pediatrics, Oncology/Hematology, University Children's Hospital Tübingen, Tübingen, Germany., Mirakaj V; Department of Anesthesia and Intensive Care Medicine, University Hospital Tübingen, Tübingen, Germany., Karbach J; Department of Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany., Jäger E; Department of Oncology and Hematology, Krankenhaus Nordwest, Frankfurt, Germany., Graf M; Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany., Gruber LC; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany., Rachfalski D; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany., Preuß B; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany., Hagelstein I; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Märklin M; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Bakchoul T; Institute for Clinical and Experimental Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany., Gouttefangeas C; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany., Kohlbacher O; Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany.; Institute for Bioinformatics and Medical Informatics, University of Tübingen, Tübingen, Germany.; Biomolecular Interactions, Max-Planck-Institute for Developmental Biology, Tübingen, Germany.; Institute for Translational Bioinformatics, University Hospital Tübingen, Tübingen, Germany., Klein R; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany., Stevanović S; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany., Rammensee HG; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany., Walz JS; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.
Jazyk: angličtina
Zdroj: Nature immunology [Nat Immunol] 2021 Jan; Vol. 22 (1), pp. 74-85. Date of Electronic Publication: 2020 Sep 30.
DOI: 10.1038/s41590-020-00808-x
Abstrakt: T cell immunity is central for the control of viral infections. To characterize T cell immunity, but also for the development of vaccines, identification of exact viral T cell epitopes is fundamental. Here we identify and characterize multiple dominant and subdominant SARS-CoV-2 HLA class I and HLA-DR peptides as potential T cell epitopes in COVID-19 convalescent and unexposed individuals. SARS-CoV-2-specific peptides enabled detection of post-infectious T cell immunity, even in seronegative convalescent individuals. Cross-reactive SARS-CoV-2 peptides revealed pre-existing T cell responses in 81% of unexposed individuals and validated similarity with common cold coronaviruses, providing a functional basis for heterologous immunity in SARS-CoV-2 infection. Diversity of SARS-CoV-2 T cell responses was associated with mild symptoms of COVID-19, providing evidence that immunity requires recognition of multiple epitopes. Together, the proposed SARS-CoV-2 T cell epitopes enable identification of heterologous and post-infectious T cell immunity and facilitate development of diagnostic, preventive and therapeutic measures for COVID-19.
Databáze: MEDLINE
Externí odkaz: